Our top pick for
Verastem, Inc is a biotechnology business based in the US. Verastem shares (VSTM) are listed on the NASDAQ and all prices are listed in US Dollars. Verastem employs 135 staff and has a trailing 12-month revenue of around USD$21.6 million.
Since the stock market crash in March caused by coronavirus, Verastem's share price has had significant negative movement.
Its last market close was USD$1.52, which is 30.28% down on its pre-crash value of USD$2.18 and 1.33% up on the lowest point reached during the March crash when the shares fell as low as USD$1.5.
If you had bought USD$1,000 worth of Verastem shares at the start of February 2020, those shares would have been worth USD$1,053.18 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth USD$808.50.
|Latest market close||USD$1.52|
|52-week range||USD$1.08 - USD$4.6699|
|50-day moving average||USD$1.3369|
|200-day moving average||USD$1.4801|
|Wall St. target price||USD$3.83|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.844|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2020-11-19)||N/A|
|1 month (2020-10-30)||26.67%|
|3 months (2020-08-26)||N/A|
|6 months (2020-05-26)||N/A|
|1 year (2019-11-26)||N/A|
|2 years (2018-11-26)||N/A|
|3 years (2017-11-26)||N/A|
|5 years (2015-11-26)||N/A|
|Revenue TTM||USD$21.6 million|
|Gross profit TTM||USD$16.2 million|
|Return on assets TTM||-39.94%|
|Return on equity TTM||-114.53%|
|Market capitalisation||USD$288.6 million|
TTM: trailing 12 months
There are currently 5.7 million Verastem shares held short by investors – that's known as Verastem's "short interest". This figure is 4.1% up from 5.5 million last month.
There are a few different ways that this level of interest in shorting Verastem shares can be evaluated.
Verastem's "short interest ratio" (SIR) is the quantity of Verastem shares currently shorted divided by the average quantity of Verastem shares traded daily (recently around 2.3 million). Verastem's SIR currently stands at 2.46. In other words for every 100,000 Verastem shares traded daily on the market, roughly 2460 shares are currently held short.
However Verastem's short interest can also be evaluated against the total number of Verastem shares, or, against the total number of tradable Verastem shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Verastem's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Verastem shares in existence, roughly 30 shares are currently held short) or 0.0374% of the tradable shares (for every 100,000 tradable Verastem shares, roughly 37 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Verastem.
Find out more about how you can short Verastem stock.
We're not expecting Verastem to pay a dividend over the next 12 months.
Over the last 12 months, Verastem's shares have ranged in value from as little as $1.08 up to $4.6699. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Verastem's is 0.7711. This would suggest that Verastem's shares are less volatile than average (for this exchange).
Verastem, Inc., a biopharmaceutical company, focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. It markets COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being investigated in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), mesothelioma, and other solid tumors. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd. and CSPC Pharmaceutical Group Limited. The company was founded in 2010 and is based in Needham, Massachusetts.
Steps to owning and managing CCF, with 24-hour and historical pricing before you buy.
Steps to owning and managing CDW, with 24-hour and historical pricing before you buy.
Steps to owning and managing CWH, with 24-hour and historical pricing before you buy.
Steps to owning and managing CBIO, with 24-hour and historical pricing before you buy.
Steps to owning and managing BLIN, with 24-hour and historical pricing before you buy.
Steps to owning and managing CVGW, with 24-hour and historical pricing before you buy.
Steps to owning and managing AEGN, with 24-hour and historical pricing before you buy.
Steps to owning and managing AJG, with 24-hour and historical pricing before you buy.
Steps to owning and managing ABB, with 24-hour and historical pricing before you buy.
Steps to owning and managing YGYI, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.